Kidney Disease: Improving Global Outcomes (KDIGO) released the 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease (CKD). Released 4 years after the previous KDIGO guideline on this subject, the updated guideline addresses new evidence in several areas, including the role of additional direct-acting antiviral regimens in treating patients with hepatitis C virus (HCV) and CKD G1-G5 or CKD G5D, including kidney transplant recipients. The guideline also addresses studies about the efficacy and safety of kidney transplantation from donors with HCV to recipients who are HCV negative, and the role of kidney biopsy in managing HCV-associated glomerulonephritis. The new guideline, an Executive Summary, and additional resources are available online.
